US Patent 10364287 Anti-CD28 humanized antibodies
All edits
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+256 characters)
Article
Patent abstract
The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28.
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 1 Apr, 2023
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
103642870
Date of Patent
July 30, 2019
0Patent Application Number
153869980
Date Filed
December 21, 2016
0Official Website
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
103642870
Date of Patent
July 30, 2019
0Patent Application Number
153869980
Date Filed
December 21, 2016
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 28 Jan, 2022
Golden AI
Edits made to:
Infobox (+7 properties)
US Patent 10364287 Anti-CD28 humanized antibodies
Infobox
Is a
Patent jurisdiction
Patent number
10364287
Date of patent
July 30, 2019
Patent application number
15386998
Date Filed
December 21, 2016
Patent primary examiner
Find more entities like US Patent 10364287 Anti-CD28 humanized antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
